CTX321 — Topline data
2026
An Lp(a) program update is anticipated in 2026.Source filing
CRSP biotech catalysts & pipeline
CRISPR THERAPEUTICS AG · Data as of 2026-09-08
Upcoming catalysts
CTX310® — Topline data
H2 2026
The Company also expects to provide a Phase 1b clinical update in the second half of 2026.Source filing
CTX611 (SRSD107) — Interim data
H2 2026
The Company expects to provide an update in the second half of 2026.Source filing
zugocabtagene geleucel (zugo-cel; formerly CTX112™) — Topline data
H2 2026
In immuno-oncology, the Phase 1/2 clinical trial of zugo-cel in B-cell malignancies is ongoing, with updates anticipated in the second half of 2026.Source filing
CTX321™ — Conference presentation
2026
CTX321 is currently in IND/CTA-enabling studies, with an Lp(a) program update expected in 2026.Source filing